Association of Celiac Disease With Pembrolizumab.
| Autor: | Sethi A; Medical Oncology, Allegheny Health Network, Pittsburgh, USA., Helfand A; Hematology & Oncology, Allegheny Health Network, Pittsburgh, USA., Balikani L; Pathology, Allegheny Health Network, Pittsburgh, USA., Bunker M; Pathology, Allegheny Health Network, Pittsburgh, USA., Finley G; Hematology & Oncology, Allegheny Health Network, Pittsburgh, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2021 Jun 10; Vol. 13 (6), pp. e15565. Date of Electronic Publication: 2021 Jun 10 (Print Publication: 2021). |
| DOI: | 10.7759/cureus.15565 |
| Abstrakt: | Immune checkpoint inhibitors (ICIs) in the recent times have transformed the landscape of the management of many solid tumors. Unfortunately, many immune-related adverse effects are associated with ICIs, which lead to a negative outcome in cancer treatment. We present a case of a 63-year-old female with metastatic adenocarcinoma of unknown origin, who developed celiac disease during the course of treatment with pembrolizumab. Association of celiac disease with this form of immunotherapy has never been documented before. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Sethi et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|